Charles River enters ADC drug discovery pact with Francis Crick Institute

Charles River (CRL) and The Francis Crick Institute announced a new collaboration around antibody-drug conjugate drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies. This agreement leverages an integrated approach to streamline discovery and characterization-bringing promising ADC candidates to the clinic faster and more efficiently. This end-to-end approach-spanning antibody discovery, conjugation, in vitro profiling, and preclinical studies-will be fully integrated and managed jointly by Charles River and the Crick to minimize timelines and maximize efficiency.